# Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome

> **NCT06801249** · PHASE4 · RECRUITING · sponsor: **IRCCS Azienda Ospedaliero-Universitaria di Bologna** · enrollment: 50 (estimated)

## Conditions studied

- Adrenal Incidentalomas
- Cushing Syndrome

## Interventions

- **DRUG:** Metarapone
- **DRUG:** Standardized antihypertensive therapy

## Key facts

- **NCT ID:** NCT06801249
- **Lead sponsor:** IRCCS Azienda Ospedaliero-Universitaria di Bologna
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-23
- **Primary completion:** 2024-11-30
- **Final completion:** 2025-02-17
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06801249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06801249, "Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06801249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*